Top global orphan drugs by revenue 2018

This statistic shows the top pharmaceutical orphan drugs worldwide based on the revenues in 2018. During that year, Revlimid marketed by Celgene was the world's top orphan drug, generating almost ten billion U.S. dollars in revenue. Orphan drugs are developed to treat a specific rare medical condition, often called an orphan disease. In many countries, public policy determines the characteristics behind specifying orphan diseases and drugs.

Top global orphan drugs by revenue in 2018 (in billion U.S. dollars)*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

April 2019

Region

Worldwide

Survey time period

2018

Supplementary notes

* Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Orphan drugs"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.